Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AcSe CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug

Trial Profile

AcSe CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic large cell lymphoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Liver cancer; Muscle tissue neoplasms; Neuroblastoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms AcSe; AcSe-CRIZOTINIB
  • Most Recent Events

    • 04 Oct 2019 Results assessing efficacy and safety using a two-stage Simon phase II trial design, published in the Annals of Oncology.
    • 26 Sep 2018 Results accessing activity of Crizotinib in NSCLC patients were presented at the 19th World Conference on Lung Cancer.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top